Şahin U - Search Results

1

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU. Mulligan MJ, et al. Among authors: sahin u. Nature. 2020 Oct;586(7830):589-593. doi: 10.1038/s41586-020-2639-4. Epub 2020 Aug 12. Nature. 2020. PMID: 32785213 Clinical Trial.

2

Serological analysis of human tumor antigens: molecular definition and implications.

Türeci O, Sahin U, Pfreundschuh M. Türeci O, et al. Among authors: sahin u. Mol Med Today. 1997 Aug;3(8):342-9. doi: 10.1016/s1357-4310(97)01081-2. Mol Med Today. 1997. PMID: 9269687 Review.

3

Identification of tumor-associated autoantigens with SEREX.

Türeci O, Usener D, Schneider S, Sahin U. Türeci O, et al. Among authors: sahin u. Methods Mol Med. 2005;109:137-54. doi: 10.1385/1-59259-862-5:137. Methods Mol Med. 2005. PMID: 15585919

4

The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes.

Koslowski M, Sahin U, Huber C, Türeci O. Koslowski M, et al. Among authors: sahin u. Hum Mol Genet. 2006 Aug 1;15(15):2392-9. doi: 10.1093/hmg/ddl163. Epub 2006 Jun 29. Hum Mol Genet. 2006. PMID: 16809397

5

In silico strategy for detection of target candidates for antibody therapy of solid tumors.

Helftenbein G, Koslowski M, Dhaene K, Seitz G, Sahin U, Türeci O. Helftenbein G, et al. Among authors: sahin u. Gene. 2008 May 15;414(1-2):76-84. doi: 10.1016/j.gene.2008.02.009. Epub 2008 Feb 19. Gene. 2008. PMID: 18358640

6

MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes.

Koslowski M, Sahin U, Dhaene K, Huber C, Türeci O. Koslowski M, et al. Among authors: sahin u. Cancer Res. 2008 May 1;68(9):3458-66. doi: 10.1158/0008-5472.CAN-07-5768. Cancer Res. 2008. PMID: 18451174

7

Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O, Sahin U. Kreiter S, et al. Among authors: sahin u. Cancer Res. 2010 Nov 15;70(22):9031-40. doi: 10.1158/0008-5472.CAN-10-0699. Epub 2010 Nov 2. Cancer Res. 2010. PMID: 21045153

8

Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics.

Kuhn AN, Diken M, Kreiter S, Vallazza B, Türeci Ö, Sahin U. Kuhn AN, et al. Among authors: sahin u. RNA Biol. 2011 Jan-Feb;8(1):35-43. doi: 10.4161/rna.8.1.13767. Epub 2011 Jan 1. RNA Biol. 2011. PMID: 21289486

9

Tumor vaccination using messenger RNA: prospects of a future therapy.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Kreiter S, et al. Among authors: sahin u. Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Curr Opin Immunol. 2011. PMID: 21497074 Review.

10

FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.

Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hüsemann Y, Koslowski M, Huber C, Türeci Ö, Sahin U. Kreiter S, et al. Among authors: sahin u. Cancer Res. 2011 Oct 1;71(19):6132-42. doi: 10.1158/0008-5472.CAN-11-0291. Epub 2011 Aug 4. Cancer Res. 2011. PMID: 21816907

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

487 results

Search Page